363 related articles for article (PubMed ID: 22512091)
1. The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway.
Wang H; Wang X; Li Y; Liao A; Fu B; Pan H; Liu Z; Yang W
Pharmazie; 2012 Feb; 67(2):187-92. PubMed ID: 22512091
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms of converting K562/DNR cellular drug-resistance by bortezomib.
Li YC; Wang HH; Liao AJ; Fu BB; Zhang R; Li J; Yang Y; Liu ZG; Yang W
Eur Rev Med Pharmacol Sci; 2014; 18(10):1465-72. PubMed ID: 24899604
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibitor bortezomib overcomes P-gp-mediated multidrug resistance in resistant leukemic cell lines.
Zheng B; Zhou R; Gong Y; Yang X; Shan Q
Int J Lab Hematol; 2012 Jun; 34(3):237-47. PubMed ID: 22145750
[TBL] [Abstract][Full Text] [Related]
4. Reversion of Multidrug-Resistance by Proteasome Inhibitor Bortezomib in K562/DNR Cell Line.
Wang HH; Li YC; Liao AJ; Fu BB; Yang W; Liu ZG; Wang XB
Chin J Cancer Res; 2011 Mar; 23(1):69-73. PubMed ID: 23467537
[TBL] [Abstract][Full Text] [Related]
5. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295
[TBL] [Abstract][Full Text] [Related]
6. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
[TBL] [Abstract][Full Text] [Related]
7. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents.
Ma MH; Yang HH; Parker K; Manyak S; Friedman JM; Altamirano C; Wu ZQ; Borad MJ; Frantzen M; Roussos E; Neeser J; Mikail A; Adams J; Sjak-Shie N; Vescio RA; Berenson JR
Clin Cancer Res; 2003 Mar; 9(3):1136-44. PubMed ID: 12631619
[TBL] [Abstract][Full Text] [Related]
8. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma/leukemia cells derived from Jurkat line.
Lü S; Chen Z; Yang J; Chen L; Gong S; Zhou H; Guo L; Wang J
Exp Hematol; 2008 Oct; 36(10):1278-84. PubMed ID: 18562081
[TBL] [Abstract][Full Text] [Related]
10. N-(4-hydroxyphenyl)retinamide inhibits invasion, suppresses osteoclastogenesis, and potentiates apoptosis through down-regulation of I(kappa)B(alpha) kinase and nuclear factor-kappaB-regulated gene products.
Shishodia S; Gutierrez AM; Lotan R; Aggarwal BB
Cancer Res; 2005 Oct; 65(20):9555-65. PubMed ID: 16230421
[TBL] [Abstract][Full Text] [Related]
11. The antiproliferation effect of berbamine on k562 resistant cells by inhibiting NF-kappaB pathway.
Wei YL; Liang Y; Xu L; Zhao XY
Anat Rec (Hoboken); 2009 Jul; 292(7):945-50. PubMed ID: 19548306
[TBL] [Abstract][Full Text] [Related]
12. [Effect of bortezomib on MAPK signaling pathway of K562/DNR cells].
Liao AJ; Fu BB; Wang HH; Li YC; Yao K; Zhang R; Yang W; Liu ZG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1460-3. PubMed ID: 21176351
[TBL] [Abstract][Full Text] [Related]
13. Bortezomib-enhanced radiosensitization through the suppression of radiation-induced nuclear factor-κB activity in human oral cancer cells.
Tamatani T; Takamaru N; Hara K; Kinouchi M; Kuribayashi N; Ohe G; Uchida D; Fujisawa K; Nagai H; Miyamoto Y
Int J Oncol; 2013 Mar; 42(3):935-44. PubMed ID: 23340716
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the mechanism involved in the As2O3-regulated decrease in MDR1 expression in leukemia cells.
Gao F; Liu J; Dong WW; Wang W; Wang Y; Cai D; Zheng Z; Sun K
Oncol Rep; 2014 Feb; 31(2):926-32. PubMed ID: 24337533
[TBL] [Abstract][Full Text] [Related]
15. NF-kappaB inhibition through proteasome inhibition or IKKbeta blockade increases the susceptibility of melanoma cells to cytostatic treatment through distinct pathways.
Amschler K; Schön MP; Pletz N; Wallbrecht K; Erpenbeck L; Schön M
J Invest Dermatol; 2010 Apr; 130(4):1073-86. PubMed ID: 19940859
[TBL] [Abstract][Full Text] [Related]
16. [Proliferation-inhibiting and multidrug-resistant reversing effect of bortezomib on human HL-60 cells].
Shang J; Chen ZZ; Wu WB; Wei TN; Chen WM
Zhonghua Xue Ye Xue Za Zhi; 2012 Nov; 33(11):911-6. PubMed ID: 23363746
[TBL] [Abstract][Full Text] [Related]
17. [NF-kappaB regulating expression of mdr1 gene and P-gp to reverse drug-resistance in leukemic cells].
Wang Y; Liu X; Zhang HT; Yu M; Wang H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):950-4. PubMed ID: 17956668
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative nuclear factor-{kappa}B subunits in head and neck cancer.
Allen C; Saigal K; Nottingham L; Arun P; Chen Z; Van Waes C
Clin Cancer Res; 2008 Jul; 14(13):4175-85. PubMed ID: 18593997
[TBL] [Abstract][Full Text] [Related]
19. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells.
Bhalla S; Balasubramanian S; David K; Sirisawad M; Buggy J; Mauro L; Prachand S; Miller R; Gordon LI; Evens AM
Clin Cancer Res; 2009 May; 15(10):3354-65. PubMed ID: 19417023
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
Mitsiades CS; McMillin D; Kotoula V; Poulaki V; McMullan C; Negri J; Fanourakis G; Tseleni-Balafouta S; Ain KB; Mitsiades N
J Clin Endocrinol Metab; 2006 Oct; 91(10):4013-21. PubMed ID: 16849420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]